Skip to main content
Top
Published in: Respiratory Research 1/2002

Open Access 01-06-2002 | Supplement

Pathophysiological mechanisms for the respiratory syncytial virus-reactive airway disease link

Author: Giovanni Piedimonte

Published in: Respiratory Research | Special Issue 1/2002

Login to get access

Abstract

There is substantial epidemiological evidence supporting the concept that respiratory syncytial virus (RSV) lower respiratory tract infection in infancy may be linked to the development of reactive airway disease (RAD) in childhood. However, much less is known concerning the mechanisms by which this self-limiting infection leads to airway dysfunction that persists long after the virus is cleared from the lungs. A better understanding of the RSV–RAD link may have important clinical implications, particularly because prevention of RSV lower respiratory tract infection may reduce the occurrence of RAD later in life. Among the mechanisms proposed to explain the chronic sequelae of RSV infection is the interaction between the subepithelial neural network of the airway mucosa and the cellular effectors of inflammatory and immune responses to the virus. The body of clinical literature linking RSV and RAD is reviewed herein, as are the cellular and molecular mechanisms of neuroimmune interactions and neural remodeling that may underlie this link, and the possibility that preventing the infection may result in a decreased incidence of its chronic sequelae.
Literature
1.
go back to reference Centers for Disease Control and Prevention: Respiratory syncytial virus activity: United States, 1999–2000 season. MMWR Morb Mortal Wkly Rep 2000, 49:1091–1093. Centers for Disease Control and Prevention: Respiratory syncytial virus activity: United States, 1999–2000 season. MMWR Morb Mortal Wkly Rep 2000, 49:1091–1093.
2.
go back to reference Sims DG, Downham MA, Gardner PS, Webb JKG, Weightman D: Study of 8-year-old children with a history of respiratory syncytial virus bronchiolitis in infancy. BMJ 1978, 1:11–14.CrossRefPubMedPubMedCentral Sims DG, Downham MA, Gardner PS, Webb JKG, Weightman D: Study of 8-year-old children with a history of respiratory syncytial virus bronchiolitis in infancy. BMJ 1978, 1:11–14.CrossRefPubMedPubMedCentral
3.
go back to reference Pullan CR, Hey EN: Wheezing, asthma, and pulmonary dysfunction 10 years after infection with respiratory syncytial virus in infancy. BMJ 1982, 284:1665–1669.CrossRefPubMedPubMedCentral Pullan CR, Hey EN: Wheezing, asthma, and pulmonary dysfunction 10 years after infection with respiratory syncytial virus in infancy. BMJ 1982, 284:1665–1669.CrossRefPubMedPubMedCentral
4.
go back to reference McConnochie KM, Roghmann KJ: Bronchiolitis as a possible cause of wheezing in childhood: new evidence. Pediatrics 1984, 74:1–10.PubMed McConnochie KM, Roghmann KJ: Bronchiolitis as a possible cause of wheezing in childhood: new evidence. Pediatrics 1984, 74:1–10.PubMed
6.
go back to reference Carlsen KH, Larsen S, Bjerve O, Laegaard J: Acute bronchiolitic pre-disposing factors and characterization of infants at risk. Pediatr Pulmonol 1987, 3:153–160.CrossRefPubMed Carlsen KH, Larsen S, Bjerve O, Laegaard J: Acute bronchiolitic pre-disposing factors and characterization of infants at risk. Pediatr Pulmonol 1987, 3:153–160.CrossRefPubMed
7.
8.
go back to reference Osundwa VM, Dawod ST, Ehlayel M: Recurrent wheezing in children with respiratory syncytial virus (RSV) bronchiolitis. Arch Dis Child 1993, 152:1001–1003. Osundwa VM, Dawod ST, Ehlayel M: Recurrent wheezing in children with respiratory syncytial virus (RSV) bronchiolitis. Arch Dis Child 1993, 152:1001–1003.
9.
go back to reference Noble V, Murray M, Webb MS, Alexander J, Swarbrick AS, Milner AD: Respiratory status and allergy nine to 10 years after acute bronchiolitis. Arch Dis Child 1997, 76:315–319.CrossRefPubMedPubMedCentral Noble V, Murray M, Webb MS, Alexander J, Swarbrick AS, Milner AD: Respiratory status and allergy nine to 10 years after acute bronchiolitis. Arch Dis Child 1997, 76:315–319.CrossRefPubMedPubMedCentral
10.
go back to reference Glezen WP, Taber LH, Frank AL, Kasel JA: Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986, 140:543–546.PubMed Glezen WP, Taber LH, Frank AL, Kasel JA: Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986, 140:543–546.PubMed
11.
go back to reference Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B: Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 2000, 161:1501–1507.CrossRefPubMed Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B: Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 2000, 161:1501–1507.CrossRefPubMed
12.
go back to reference Stein RT, Sherrill D, Morgan WJ, Holber CJ, Holonen M, Taussig LM, Wright AL, Martinez FD: Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999, 354:541–545.CrossRefPubMed Stein RT, Sherrill D, Morgan WJ, Holber CJ, Holonen M, Taussig LM, Wright AL, Martinez FD: Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999, 354:541–545.CrossRefPubMed
13.
go back to reference Piedimonte G, Rodriguez MM, King KA, Mclean S, Jiang X: Respiratory syncytial virus upregulates expression of the substance P receptor in rat lungs. Am J Physiol 1999, 277:L831-L840.PubMed Piedimonte G, Rodriguez MM, King KA, Mclean S, Jiang X: Respiratory syncytial virus upregulates expression of the substance P receptor in rat lungs. Am J Physiol 1999, 277:L831-L840.PubMed
14.
go back to reference King KA, Hu C, Rodriguez MM, Romaguera R, Jiang X, Piedimonte G: Exaggerated neurogenic inflammation and substance P receptor upregulation in RSV-infected weanling rats. Am J Respir Cell Mol Biol 2001, 24:101–107.CrossRefPubMed King KA, Hu C, Rodriguez MM, Romaguera R, Jiang X, Piedimonte G: Exaggerated neurogenic inflammation and substance P receptor upregulation in RSV-infected weanling rats. Am J Respir Cell Mol Biol 2001, 24:101–107.CrossRefPubMed
15.
go back to reference Wedde-Beer K, Hu C, Rodriguez MM, Piedimonte G: Leukotrienes mediate neurogenic inflammation in lungs of young rats infected with respiratory syncytial virus. Am J Physiol Lung Cell Mol Physiol 2002, 282:L1143-L1150.CrossRefPubMed Wedde-Beer K, Hu C, Rodriguez MM, Piedimonte G: Leukotrienes mediate neurogenic inflammation in lungs of young rats infected with respiratory syncytial virus. Am J Physiol Lung Cell Mol Physiol 2002, 282:L1143-L1150.CrossRefPubMed
16.
go back to reference Hu C, Wedde-Beer K, Auais A, Rodriguez MM, Piedimonte G: Nerve growth factor (NGF) and NGF receptors in respiratory syncytial virus (RSV)-infected lungs. Am J Physiol Lung Cell Mol Physiol 2002, 10.1152/ajplung.00414.2001. Hu C, Wedde-Beer K, Auais A, Rodriguez MM, Piedimonte G: Nerve growth factor (NGF) and NGF receptors in respiratory syncytial virus (RSV)-infected lungs. Am J Physiol Lung Cell Mol Physiol 2002, 10.1152/ajplung.00414.2001.
17.
go back to reference Simoes EAF: Treatment and prevention of respiratory syncytial virus lower respiratory tract infection. Long-term effects on respiratory outcomes. Am J Respir Crit Care Med 2001, 163:S14-S17.CrossRefPubMed Simoes EAF: Treatment and prevention of respiratory syncytial virus lower respiratory tract infection. Long-term effects on respiratory outcomes. Am J Respir Crit Care Med 2001, 163:S14-S17.CrossRefPubMed
18.
go back to reference The IMpact-RSV Study group: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102:531–537.CrossRef The IMpact-RSV Study group: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102:531–537.CrossRef
19.
go back to reference Piedimonte G, King KA, Holmgren NL, Bertrand PJ, Rodriguez MM, Hirsch RL: A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways. Pediatr Res 2000, 47:351–356.CrossRefPubMed Piedimonte G, King KA, Holmgren NL, Bertrand PJ, Rodriguez MM, Hirsch RL: A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways. Pediatr Res 2000, 47:351–356.CrossRefPubMed
20.
go back to reference Wenzel SE, Gibbs R, Lehr MV, Simoes EAF: Respiratory outcomes in high-risk children 7–10 years after prophylaxis with respiratory syncytial virus immune globulin. Am J Med 2002, 112:627–633.CrossRefPubMed Wenzel SE, Gibbs R, Lehr MV, Simoes EAF: Respiratory outcomes in high-risk children 7–10 years after prophylaxis with respiratory syncytial virus immune globulin. Am J Med 2002, 112:627–633.CrossRefPubMed
Metadata
Title
Pathophysiological mechanisms for the respiratory syncytial virus-reactive airway disease link
Author
Giovanni Piedimonte
Publication date
01-06-2002
Publisher
BioMed Central
Published in
Respiratory Research / Issue Special Issue 1/2002
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/rr185

Other articles of this Special Issue 1/2002

Respiratory Research 1/2002 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine